CDC Protocol Outcomes in Type 2 Diabetes at Navi Mumbai-AIroli: Hba1c Response and Anthropometric Changes in 17 Dm Package Patients — A Retrospective Analysis

Background: Navi Mumbai-Airoli's DM Package cohort is predominantly female (52.9%) with moderate baseline glycaemic control (HbA1c 8.85%). As a smaller satellite clinic, it provides focused evidence for CDC protocol efficacy in the Airoli residential community. Objective: To evaluate the effect of the Madhavbaug CDC Panchakarma-based multimodal protocol on glycaemic, anthropometric, cardiometabolic, and medication parameters exclusively in DM Package patients (n=17) at the Navi Mumbai (Airoli) Central RIC clinic. Methods: Retrospective observational study. 17 T2DM patients enrolled in the DM Package at Navi Mumbai (Airoli) Central RIC. Only DM Package care plans (CDC-SP Base/1/2/3, CDC-KP Base/1/2/3, DM-HTN 1/2/3) included. Paired Student's t-test (two-tailed) for within-group pre–post comparisons (p<0.05 significant). Descriptive statistics as mean ± SD. Results: HbA1c declined significantly from 8.79±2.13% to 7.36±0.94% (Δ −1.43%, −16.3%, p=0.032, n=12). Weight reduced from 68.49±9.50 to 66.54±9.98 kg (Δ −1.96 kg, −2.9%, p=0.009, n=16). RBS showed minimal change (−2.79 mg/dL, p=0.893), likely due to heterogeneous follow-up timing. BMI trend: −1.00 kg/m² (−3.7%, p=0.086, n=7). Conclusion: Navi Mumbai-Airoli's DM Package demonstrates significant HbA1c reduction of 16.3% (8.79% → 7.36%, p=0.032) and weight reduction of 2.9% (p=0.009), confirming the CDC protocol's glycaemic and anthropometric efficacy in this smaller clinic cohort. The non-significant RBS change likely reflects limited paired data and variable follow-up rather than absent effect.